2. Academic Validation
  3. Human type III collagen-derived biomaterial with high antitumor activity inhibits breast cancer cell autophagy, proliferation, and migration through DDR1

Human type III collagen-derived biomaterial with high antitumor activity inhibits breast cancer cell autophagy, proliferation, and migration through DDR1

  • Int J Biol Macromol. 2023 May 30;125130. doi: 10.1016/j.ijbiomac.2023.125130.
Xiaowei Liu 1,  Hu Li 2,  Tingrui Wang 1,  Ting Yang 1,  Xia Yang 3,  Kaixuan Guo 3,  Lina Hu 4,  Jia Ming 5
Affiliations

Affiliations

  • 1 Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
  • 2 Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
  • 3 Shanxi Key Laboratory of Functional Proteins, Shanxi Jinbo Bio-Pharmaceutical Co., Ltd., Taiyuan 030032, Shanxi, China.
  • 4 Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China; Joint International Research Lab for Reproduction and Development, Ministry of Education, Chongqing 400010, China; Reproduction and Stem Cell Therapy Research Center of Chongqing, Chongqing 400010, China. Electronic address: [email protected].
  • 5 Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China. Electronic address: [email protected].
PMID: 37263336 DOI: 10.1016/j.ijbiomac.2023.125130
Abstract

Breast Cancer (BC) has become the most common Cancer in the world and lacks safe and efficient treatment. The novel biomaterial recombinant humanized type III collagen (rhCOLIII) has been reported to have various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment, but its role in breast Cancer is unclear. In this study, we first found that rhCOLIII inhibited the proliferation, migration, and invasion of breast Cancer cells (BCCs) but had no effect on the survival of normal breast epithelial cells. In addition, rhCOLIII not only promoted Apoptosis and dormancy of BCCs but also inhibited Autophagy within BCCs. Subsequently, RNA-Seq analysis suggested that DDR1 may be a key target for rhCOLIII to exert antitumor effects and validated that inhibition of DDR1 eliminated the effects of rhCOLIII on the proliferation, migration, Apoptosis, dormancy and Autophagy of BCCs. Moreover, rhCOLIII treatment was found to reduce the tumorigenic activity of BCCs in animal experiments and to upregulate DDR1 protein expression while inhibiting Autophagy at the tissue level. Therefore, rhCOLIII may serve as a potential treatment method for BC patients and is expected to improve the prognosis of patients.

Keywords

Autophagy; Breast cancer; DRR1; Recombinant humanized type III collagen.

Figures
Products